Efficacy and Safety of Dual Anti-HER2 Blockade and Docetaxel With or Without Carboplatin as Neoadjuvant Regimen for Treatment of HER2-Positive Breast Cancer

Introduction: This study aimed to compare the efficacy and safety of docetaxel + trastuzumab + pertuzumab and docetaxel + carboplatin + trastuzumab + pertuzumab for treating HER2-positive breast cancer. Method: HER2-positive breast cancer from patients diagnosed between January 2020 and September 20...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Binwei, Fan, Jinjia, Liu, Fang, Wen, Yixue, Li, Jie, Gao, Feng, Zhang, Yu, Feng, Gang, Du, Xiaobo, Chen, Wenzhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Navigating Breast Health: From Screening to Survivorship
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687954/
https://www.ncbi.nlm.nih.gov/pubmed/38031361
http://dx.doi.org/10.1177/15330338231218152

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687954/
https://www.ncbi.nlm.nih.gov/pubmed/38031361
http://dx.doi.org/10.1177/15330338231218152

Ejemplares similares